SG11201503231YA - METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES - Google Patents

METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES

Info

Publication number
SG11201503231YA
SG11201503231YA SG11201503231YA SG11201503231YA SG11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA SG 11201503231Y A SG11201503231Y A SG 11201503231YA
Authority
SG
Singapore
Prior art keywords
aureus
treating
methods
associated diseases
diseases
Prior art date
Application number
SG11201503231YA
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Melissa Hamilton
Lei Hua
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201503231YA publication Critical patent/SG11201503231YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201503231YA 2012-11-06 2013-11-05 METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES SG11201503231YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (1)

Publication Number Publication Date
SG11201503231YA true SG11201503231YA (en) 2015-05-28

Family

ID=50685101

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201503231YA SG11201503231YA (en) 2012-11-06 2013-11-05 METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
SG10201703677VA SG10201703677VA (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201703677VA SG10201703677VA (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20210083389A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG11201503231YA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
US12264194B2 (en) 2019-03-13 2025-04-01 Medimmune, Llc Decreasing Staphylococcus aureus infections in colonized patients
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053235A1 (en) * 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2011008939A2 (en) * 2009-07-16 2011-01-20 Medical College Of Georgia Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
CA2825770A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
KR102272744B1 (ko) 2021-07-06
JP6926138B2 (ja) 2021-08-25
MX367082B (es) 2019-08-05
SG10201703677VA (en) 2017-06-29
EP2928490A4 (en) 2016-11-02
KR20150092738A (ko) 2015-08-13
AU2018236849A1 (en) 2018-10-18
CN112316135A (zh) 2021-02-05
BR112015010126A2 (enExample) 2017-08-22
JP6506172B2 (ja) 2019-04-24
BR112015010126B1 (pt) 2022-11-01
US10759849B2 (en) 2020-09-01
US20190002540A1 (en) 2019-01-03
WO2014074470A1 (en) 2014-05-15
JP2019142888A (ja) 2019-08-29
CA2890385C (en) 2022-07-12
RU2015121617A (ru) 2016-12-27
CA2890385A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
US9845348B2 (en) 2017-12-19
EP2928490A1 (en) 2015-10-14
JP2015536951A (ja) 2015-12-24
EP2928490B1 (en) 2022-03-30
US20160257733A1 (en) 2016-09-08
US20200109191A1 (en) 2020-04-09
AU2013341421A1 (en) 2015-06-04
US10457724B2 (en) 2019-10-29
HK1215173A1 (zh) 2016-08-19
CN104780934A (zh) 2015-07-15
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
AU2018236849B2 (en) 2020-05-21
KR20210083389A (ko) 2021-07-06
KR20200102533A (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
PT2683384E (pt) Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
BR112014007603A2 (pt) métodos de tratamento do câncer
EP2790622A4 (en) LITHOTRITIC OCULAR TREATMENT
DK3292875T3 (en) Compositions and methods for treating diseases
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
GB201504002D0 (en) Treatment of intracellular bacterial infection
GB201506561D0 (en) Treatment of amblyopia
ZA201502945B (en) Platelet targeted treatment
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IL239273A0 (en) A method of treating diseases
ZA201501430B (en) Heterocyclyl carboxamides for treating viral diseases
ZA201308194B (en) Treatment of mastitis
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
EP2911662A4 (en) METHOD OF TREATING A DISEASE
HK40043513B (en) Interval therapy for the treatment of eye diseases
GB201204645D0 (en) Treatment of disease
AU2012900983A0 (en) Novel antibacterial animal therapy
AU2013905016A0 (en) Treatment of animal fibres
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment